ecrin-mdr-crcClinical2020IPD Sharing (as of September 2023): NoNeoplasm MetastasisNSCLCColon CancerNon-small cell lung cancerColorectal CancerAdvanced Solid TumorsAdvanced CancerPancreatic CancerMetastatic CancerNeoplasmsMalignant Neoplastic DiseaseNeoplasm MetastasisNsclcColon CancerColorectal CancerAdvanced Solid TumorsNon-small Cell Lung CancerAdvanced CancerPancreatic CancerMetastatic CancerNeoplasmsMalignant Neoplastic DiseaseInterventionalhttps://newmdr.ecrin.org/Study/2334803United States4SHP2KRAS G12CAdagrasibECRIN MDRActive, not recruitingfalseAdagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.2020-04-152334803NCT04330664